32
Participants
Start Date
January 31, 2012
Primary Completion Date
February 28, 2014
Study Completion Date
July 31, 2015
Continuous 3,4-DAP
Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
Taper 3,4-DAP to Placebo
Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
Duke University, Durham
Vanderbilt University Medical Center, Nashville
Indiana University, Indianapolis
Baylor College of Medicine, Houston
University of Utah, Salt Lake City
University of California at Davis, Sacramento
Oregon Health & Science University, Portland
Lead Sponsor
Jacobus Pharmaceutical
INDUSTRY